Marrone Bio Innovations (NASDAQ:MBII) is set to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Marrone Bio Innovations to post earnings of ($0.05) per share for the quarter.
Marrone Bio Innovations (NASDAQ:MBII) last posted its quarterly earnings data on Thursday, March 14th. The basic materials company reported ($0.05) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.05). Marrone Bio Innovations had a negative return on equity of 110.20% and a negative net margin of 95.26%. The firm had revenue of $5.72 million for the quarter, compared to analyst estimates of $5.03 million. On average, analysts expect Marrone Bio Innovations to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Marrone Bio Innovations stock opened at $1.54 on Tuesday. Marrone Bio Innovations has a one year low of $1.10 and a one year high of $2.18. The company has a quick ratio of 1.94, a current ratio of 2.66 and a debt-to-equity ratio of 1.48.
In other Marrone Bio Innovations news, major shareholder Van Herk Investments B.V. sold 1,500,000 shares of the firm’s stock in a transaction on Thursday, February 21st. The stock was sold at an average price of $1.57, for a total transaction of $2,355,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.90% of the stock is owned by company insiders.
An institutional investor recently raised its position in Marrone Bio Innovations stock. Geode Capital Management LLC grew its holdings in Marrone Bio Innovations Inc (NASDAQ:MBII) by 5.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 443,611 shares of the basic materials company’s stock after purchasing an additional 24,460 shares during the period. Geode Capital Management LLC owned approximately 0.40% of Marrone Bio Innovations worth $652,000 as of its most recent SEC filing. 42.14% of the stock is owned by institutional investors and hedge funds.
Separately, National Securities restated a “buy” rating and set a $2.50 price objective on shares of Marrone Bio Innovations in a research note on Thursday, April 25th.
ILLEGAL ACTIVITY NOTICE: “Marrone Bio Innovations (MBII) to Release Quarterly Earnings on Thursday” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thelincolnianonline.com/2019/05/07/marrone-bio-innovations-mbii-to-release-quarterly-earnings-on-thursday.html.
Marrone Bio Innovations Company Profile
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.
Further Reading: What defines an oversold asset?
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.